Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY26 Earnings Presentation
26 slides from Dishman Carbogen Amcis's earnings presentation, Aug 13, 2025
Slide 1: Exchange filing cover letter for investor presentation
13th August, 2025 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code N
Slide 2: Investor Presentation Quarter ended June 30, 2025
Investor Presentation Quarter ended June 30, 2025
Slide 3: Safe Harbor Statement
This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial
Slide 4: Dishman in a Nutshell
Solving Complex Problems for 23 28 4 250+ Clients Multi-Purpose MANUFACTURING FACILITIES Globally RESEARCH & DEVELOPMENT and HIPO LABS Successful IN-ORGANIC GROWTH TRANSACTIONS DISHMAN IN 4 decades of Long-Standing Track Record in Global Health Authorities Approved & Recognized by CHF 117 M NEW PROD
Slide 5: Historical Performance at a Glance
Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA % EBITDA EBITDA % 17.3% 15.5% Strong basket of 12 APIs in Late 14.3% 13.8% 11.0% Phase III development. Focused on improving capacity 19,120 24,129 27,115 21,407 26,158 HISTORICAL 3,322 2,743 3,314 2,865 4,690 utilization by targeting small
Slide 6: Agenda
AGENDA 01 02 03 Quarter Company Industry Highlights Overview Overview
Slide 7: Quarter Highlights
01 Section Divider 01 02 03 Quarter Company Industry Highlights Overview Overview
Slide 8: Q1FY26 Result Highlights
NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 19.9% 5.5% 5,238 7,081 290 1407 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY26 RESULT Segment Wise Revenue Breakup (₹ mn) HIGHLIGHTS 968 1,023 4,215 6,113 Q1FY25 Q1FY26 CDMO Marketable Molecules 7
Slide 9: Consolidated P&L Statement
Particulars (₹ mn) Q1 FY26 Q1 FY25 YoY % Income from Operations (Net) 7,080.5 5,237.8 35.2% COGS 980.9 663.5 47.8% Employee Expenses 3,519.0 3,168.2 11.1% Other Expenses 1,173.8 1,116.4 5.1% EBITDA 1,406.8 289.7 385.6% CONSOLIDATED EBIDTA Margin % Other Income 19.9% 247.5 5.5% 14.3 P&L Depreciation
Slide 10: Revenue & Margin Breakup Analysis
Revenue (₹ mn) Q1 FY26 Q1 FY25 YoY % CDMO 6,112.5 4,214.6 45.03% Marketable Molecules 968.0 1,023.2 -5.39% REVENUE & Total Revenue 7,080.5 5,237.8 MARGIN BREAKUP EBITDA Margin % Q1 FY26 Q1 FY25 ANALYSIS CDMO 17.9% 5.8% Marketable Molecules 32.4% 4.5% Total Revenue 7,080.5 5,237.8 9
Slide 11: Revenue Break-up
Total Operating Revenue – Q1 FY26 13.7% Q1 FY26 REVENUE BREAK-UP 86.3% CDMO Marketable Molecules
Slide 12: Q1FY26 Result Highlights
Net Revenue at Rs 7,080 mn in Q1 FY26 up by 35.2% YoY mainly due to increase in revenue in the CDMO segment. CDMO revenue increased by 45.0% YoY in Q1 FY26 primarily due to increase in development revenue at the Swiss entity and French entity. MM revenue decreased by 5.4% YoY in Q1 FY26 primarily
Slide 13: ADC & Bioconjugation Business
1.1 Section Divider 1.1 02 03 ADC & BICONJUGATION Company Industry Overview Overview BUSINESS
Slide 14: ADC & Bioconjugation Integrated Business at CGAM / DCAL
BIO-CONJUGATION Services DL/BDS/DP GMP-manufacturing Process Transfer/development/validation ICH Stability QC&A Transfer/development/validation End-to-end RA support ADC & Bioconjugation Integrated DL BDS DP Business at Drug Linker* Bulk Drug Substance Drug Product GMP-manufacture GMP-manu
Slide 15: ADC & Bioconjugation Integrated Business at CGAM / DCAL
ADC & Bioconjugation Integrated Client base is from small biotech up to the biggest pharma Business at 30% companies Successful success rate collaboration CGAM / DCAL so far agreements with start-up companies More alliances with potential Dozens of quotes partners under for multiple discussions diff
Slide 16: Company Overview
02 Section Divider 02 01 03 Company Quarter Industry Overview Highlights Overview
Slide 17: About Us
Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceu
Slide 18: Manufacturing Facilities
Superior Chemistry Skills & Capabilities Facilities are approved by recognized health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA, NMPA 28 dedicated R&D labs with multiple shift R&D operations, including HIPO labs 25 multi-purpose facilities at CARBO GEN AMCIS BV., Veenendaal, The C
Slide 19: One of the Preferred Global Outsourcing Partners
CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING THE VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES ONE OF THE PREFERRED Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage GLO
Slide 20: Integrated CDMO Player
From Pre-clinical Development To Global Commercial Launch – All Under One Roof Integrated CDMO Player – Strong Capabilities across Value Chain Drug substance & Drug product Pre-clinical Phase I Phase II Phase III Market Early Stage Late Stage Commercial Supply Process Research and API supply to Proc
Slide 21: Cutting Edge HIPO Capabilities
The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full-scale manufacturing units to cater to both small volume and large volume orders. State of the art containment services, with all cGMP co
Slide 22: Industry Overview
03 Section Divider 03 01 02 Industry Quarter Company Overview Highlights Overview
Slide 23: Top 20 Therapy Areas (US$ bn) - 2029
Oncology & Obesity expected to lead growth 5-Yr CAGR 2024-2029 Oncology 441 11-14% Diabetes 259 6-9% Expected Immunology Cardiovascular 119 234 4-7% 0-3% Top 20 Therapy Areas (US$ bn) - 2029 CNS 109 6-9% Global Respiratory Other endocrine… 96 108 5-8% 5-8% Infectious diseases 80 Oncology continues
Slide 24: Specialty medicines share of spending
Specialty medicines will represent about 46% of global spending in 2029 and 56% of total spending in developed markets 54% 51% 45% 46% Specialty 42% 38% 36% 35% medicines 33% 31% 27% share of 24% 18% spending 11% 14% 8% 2014 2019 2024 2029 Pharmerging Other Developed Global 10 Developed Source: IQVI
Slide 25: June Shareholding Pattern
NSE Ticker DCAL BSE Ticker 540701 June Share Price (₹)^ 250.95 2025 Market Cap (₹ Mn )^ 39,345 % Free Float^ 40.68% Shareholding Free float market cap (₹ Mn )^ 16,005 Pattern Shares outstanding^ 15,67,83,095 PROMOTER 59.32% 3M ADTV (Shares) 5,41,949 DII 1.27% FII 9.93% 3M ADTV (₹ Mn) 132 Others 29.4
Slide 26: Thank you
Thank you FOR FURTHER QUERIES Arpit Mundra | Krishna Patel Mr. Harshil Dalal Ernst & Young LLP Global CFO Email: arpit.mundra@in.ey.com Email: harshil.dalal@dishmangroup.com krishna.patel2@in.ey.com Dishman Carbogen Amcis Ltd Dishman Corporate House Iscon-Bopal Road, Ambli Ahmedabad – 380058 Gujarat
Dishman Carbogen Amcis — Q1 FY26 Earnings Presentation on 6ix